Yoojeong Seo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yoojeong Seo has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Jae-Il Park
Department of Experimental Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
7 shared publications Jie Zhang
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
5 shared publicationsSohee Jun
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
5 shared publicationsJinho Jang
Department of Experimental Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
4 shared publications- Jinho Jang
Department of Experimental Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
3 shared publications - Kyung-Pil Ko
Department of Experimental Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
3 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (4) , 635-654
Biology and preclinical models of colorectal cancer metastasis
Metastatic colorectal cancer (mCRC) is the principal cause of CRC-related mortality, yet the biology of mCRC remains only partly understood and challenging to interrogate experimentally. Despite recent progress in mapping recurrent genetic and epigenetic alterations and treatment responses of mCRC, these efforts provide limited insight into how heterogeneous primary tumors breach tissue barriers, survive in circulation, and colonize distant organs. In this review, we summarize current experimental systems for studying mCRC, including genetically engineered mouse models, carcinogen-induced and transplant models, and patient-derived organoid and xenograft platforms, and discuss how each captures or fails to capture key steps of the metastatic cascade and organ-specific microenvironments. We highlight practical obstacles to longitudinal sampling and quantitative readouts of metastatic burden, as well as conceptual gaps in modeling immune and stromal influences. Finally, we outline how emerging approaches, including single-cell and spatial transcriptomics, and advances in longitudinal tracking of metastatic burden could be combined into an integrated framework that more faithfully links mechanistic insight to clinical behavior and ultimately to metastasis-specific therapies.
- 31 October 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (4) , 635-654
Open AccessBiology and preclinical models of colorectal cancer metastasis
Metastatic colorectal cancer (mCRC) is the principal cause of CRC-related mortality, yet the biology of mCRC remains only partly understood and challenging to interrogate experimentally. Despite recent progress in mapping recurrent genetic and epigenetic alterations and treatment responses of mCRC, these efforts provide limited insight into how heterogeneous primary tumors breach tissue barriers, survive in circulation, and colonize distant organs. In this review, we summarize current experimental systems for studying mCRC, including genetically engineered mouse models, carcinogen-induced and transplant models, and patient-derived organoid and xenograft platforms, and discuss how each captures or fails to capture key steps of the metastatic cascade and organ-specific microenvironments. We highlight practical obstacles to longitudinal sampling and quantitative readouts of metastatic burden, as well as conceptual gaps in modeling immune and stromal influences. Finally, we outline how emerging approaches, including single-cell and spatial transcriptomics, and advances in longitudinal tracking of metastatic burden could be combined into an integrated framework that more faithfully links mechanistic insight to clinical behavior and ultimately to metastasis-specific therapies.
- Open Access
- 7 October 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58 (10) , 3301-3311
Cell plasticity in cancer and therapy resistance
Cancer cell plasticity, the ability of tumor cells to switch between distinct cellular states, has emerged as a key mechanism driving tumor progression, metastasis and therapy resistance. Cancer cells exploit diverse plasticity mechanisms, including dedifferentiation, transdifferentiation, epithelial–mesenchymal transition and stem cell-like reprogramming, to adapt to changes in their microenvironment or therapeutic pressures. These transitions are orchestrated by signaling pathways, epigenetic modifications and microenvironmental cues. Notably, plasticity encompasses reversible transitions among intermediate states that enhance metastatic potential and contribute to therapeutic failure. Tumor cells can enter drug-tolerant reversible states, enabling survival during treatment and leading to relapse. Recent advances in single-cell and spatial transcriptomics, along with conceptual frameworks such as the Waddington landscape, have provided new insights into the dynamic regulation of tumor cell-state transitions at high resolution. In this Review, we discuss the molecular and cellular mechanisms governing cancer cell plasticity, its impact on metastasis and therapy resistance, and recent technological advances that illuminate dynamic tumor cell-state transitions.
- 7 October 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58 (10) , 3301-3311
Open AccessCell plasticity in cancer and therapy resistance
Cancer cell plasticity, the ability of tumor cells to switch between distinct cellular states, has emerged as a key mechanism driving tumor progression, metastasis and therapy resistance. Cancer cells exploit diverse plasticity mechanisms, including dedifferentiation, transdifferentiation, epithelial–mesenchymal transition and stem cell-like reprogramming, to adapt to changes in their microenvironment or therapeutic pressures. These transitions are orchestrated by signaling pathways, epigenetic modifications and microenvironmental cues. Notably, plasticity encompasses reversible transitions among intermediate states that enhance metastatic potential and contribute to therapeutic failure. Tumor cells can enter drug-tolerant reversible states, enabling survival during treatment and leading to relapse. Recent advances in single-cell and spatial transcriptomics, along with conceptual frameworks such as the Waddington landscape, have provided new insights into the dynamic regulation of tumor cell-state transitions at high resolution. In this Review, we discuss the molecular and cellular mechanisms governing cancer cell plasticity, its impact on metastasis and therapy resistance, and recent technological advances that illuminate dynamic tumor cell-state transitions.
- Open Access
- 6 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
RhoA Y42C drives cell plasticity and PD-1-mediated immune evasion of diffuse gastric cancer
Diffuse gastric cancer (DGC) is an aggressive gastric cancer subtype with a poor prognosis. The RHOA Y42C mutation is recurrent in DGC, but its independent oncogenic role is unclear. Next-Generation Sequencing of 431 DGC cases revealed that most RHOA mutations occurred without CDH1 alterations. Using genetically engineered gastric organoids, we show that RhoaY42C, along with KrasG12D and Trp53 loss (RKP), induces DGC, independently of Cdh1 loss. Single-cell and spatial transcriptomics reveal that RKP tumors exhibit mucinous histopathology and a specific lineage trajectory from Aqp5+ cells to Muc1/Muc4+ cells. RKP tumors create an immunosuppressive tumor microenvironment where AREG, transactivated by RhoA Y42C–YAP1, causes T cell exhaustion via PD-1 upregulation. Unlike E-cadherin loss-associated DGC, RKP tumors are highly susceptible to PD-1 blockade. Additionally, the RHOA Y42C mutation correlates with PD-1 upregulation in human DGC samples. These findings redefine the oncogenic role of RhoA Y42C, confirming its sufficiency for DGC development and suggesting PD-1 inhibition as a viable therapeutic option for DGC patients carrying this mutation.
- 6 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessRhoA Y42C drives cell plasticity and PD-1-mediated immune evasion of diffuse gastric cancer
Diffuse gastric cancer (DGC) is an aggressive gastric cancer subtype with a poor prognosis. The RHOA Y42C mutation is recurrent in DGC, but its independent oncogenic role is unclear. Next-Generation Sequencing of 431 DGC cases revealed that most RHOA mutations occurred without CDH1 alterations. Using genetically engineered gastric organoids, we show that RhoaY42C, along with KrasG12D and Trp53 loss (RKP), induces DGC, independently of Cdh1 loss. Single-cell and spatial transcriptomics reveal that RKP tumors exhibit mucinous histopathology and a specific lineage trajectory from Aqp5+ cells to Muc1/Muc4+ cells. RKP tumors create an immunosuppressive tumor microenvironment where AREG, transactivated by RhoA Y42C–YAP1, causes T cell exhaustion via PD-1 upregulation. Unlike E-cadherin loss-associated DGC, RKP tumors are highly susceptible to PD-1 blockade. Additionally, the RHOA Y42C mutation correlates with PD-1 upregulation in human DGC samples. These findings redefine the oncogenic role of RhoA Y42C, confirming its sufficiency for DGC development and suggesting PD-1 inhibition as a viable therapeutic option for DGC patients carrying this mutation.
- Open Access
- 1 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
CRACD loss drives hypoxia-induced immune escape in gastric cancer
Mucinous gastric adenocarcinoma (MGC) is a distinct histologic subtype characterized by poor prognosis and limited responsiveness to chemotherapy and immunotherapy. CRACD, an actin polymerization regulator, is frequently inactivated in gastric cancer (GC), with enrichment in mucinous subtypes. We found that genetic engineering of murine gastric organoids with Cracd ablation combined with Kras mutation and Trp53 loss induced mucinous cell plasticity, disrupted epithelial integrity, and promoted immune evasion. Mechanistically, CRACD loss triggered actin dysregulation, which activated the NF-kB/COX2 signaling and NADPH oxidase-dependent ROS generation. The resulting oxidative stress stabilized HIF1α and transactivated PD-L1 , thereby disrupting anti-tumor immunity. Pharmacologic inhibition of HIF1α or PD-L1 restored immune surveillance and suppressed tumorigenesis. Clinically, analysis of patient-derived organoids and tissue microarrays demonstrated the inverse correlation between CRACD and PD-L1 expression. These findings identify CRACD inactivation as a crucial event in mucinous plasticity and immune escape in GC, further proposing that the HIF1α-PD-L1 axis is a therapeutic vulnerability in CRACD-inactivated GC.
- 1 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessCRACD loss drives hypoxia-induced immune escape in gastric cancer
Mucinous gastric adenocarcinoma (MGC) is a distinct histologic subtype characterized by poor prognosis and limited responsiveness to chemotherapy and immunotherapy. CRACD, an actin polymerization regulator, is frequently inactivated in gastric cancer (GC), with enrichment in mucinous subtypes. We found that genetic engineering of murine gastric organoids with Cracd ablation combined with Kras mutation and Trp53 loss induced mucinous cell plasticity, disrupted epithelial integrity, and promoted immune evasion. Mechanistically, CRACD loss triggered actin dysregulation, which activated the NF-kB/COX2 signaling and NADPH oxidase-dependent ROS generation. The resulting oxidative stress stabilized HIF1α and transactivated PD-L1 , thereby disrupting anti-tumor immunity. Pharmacologic inhibition of HIF1α or PD-L1 restored immune surveillance and suppressed tumorigenesis. Clinically, analysis of patient-derived organoids and tissue microarrays demonstrated the inverse correlation between CRACD and PD-L1 expression. These findings identify CRACD inactivation as a crucial event in mucinous plasticity and immune escape in GC, further proposing that the HIF1α-PD-L1 axis is a therapeutic vulnerability in CRACD-inactivated GC.
- Open Access
NFATc3 Enhances DREAM Complex-Driven Transactivation
The nuclear factor of activated T cells (NFAT) transcription factors, activated by calcium-calcineurin signaling, regulate various cellular processes, including cell differentiation, angiogenesis, and immune cell activation. Nonetheless, their roles in tumor cells remain largely undefined. The dimerization partner, RB-like, E2F, and multi-vulval class B (DREAM) complex orchestrates cell quiescence and proliferation. Pharmacological mimicry of DREAM-activated transcriptional signatures identified two calcium signaling inhibitors that suppressed lung adenocarcinoma (LUAD) cell proliferation. Among the five NFAT members, NFATc3/NFAT4 was predominantly expressed in LUAD cells and required for both LUAD cell proliferation and DREAM target gene transactivation. NFATc3 was enriched at DREAM target promoters and associated with the DREAM complex, possibly via LIN9, a scaffolding protein of the Multi-Vulva class B (MuvB) core proteins. These findings reveal an unexpected role for NFATc3 in promoting DREAM target gene transactivation and suggest the calcium-NFATc3 axis as a molecular target in LUAD, enriched by DREAM complex activation.
Open AccessNFATc3 Enhances DREAM Complex-Driven Transactivation
The nuclear factor of activated T cells (NFAT) transcription factors, activated by calcium-calcineurin signaling, regulate various cellular processes, including cell differentiation, angiogenesis, and immune cell activation. Nonetheless, their roles in tumor cells remain largely undefined. The dimerization partner, RB-like, E2F, and multi-vulval class B (DREAM) complex orchestrates cell quiescence and proliferation. Pharmacological mimicry of DREAM-activated transcriptional signatures identified two calcium signaling inhibitors that suppressed lung adenocarcinoma (LUAD) cell proliferation. Among the five NFAT members, NFATc3/NFAT4 was predominantly expressed in LUAD cells and required for both LUAD cell proliferation and DREAM target gene transactivation. NFATc3 was enriched at DREAM target promoters and associated with the DREAM complex, possibly via LIN9, a scaffolding protein of the Multi-Vulva class B (MuvB) core proteins. These findings reveal an unexpected role for NFATc3 in promoting DREAM target gene transactivation and suggest the calcium-NFATc3 axis as a molecular target in LUAD, enriched by DREAM complex activation.
- Open Access
- 9 December 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (3) , 439-451
Dose-Response Relationship of Niclosamide and Metformin Combination in Apc Min/+ Mice: An Integrated In Vivo and Pharmacokinetic Modeling Study
Joyeon Kang, Dong Keon Kim, Yoojeong Seo, Jongwook Yu, Hyeon Hee Lee, Jihye Park, Jae Jun Park, Jae Hee Cheon, Soo Jung Park, Tae Il Kim. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250294
- 9 December 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (3) , 439-451
Open AccessDose-Response Relationship of Niclosamide and Metformin Combination in Apc Min/+ Mice: An Integrated In Vivo and Pharmacokinetic Modeling Study
Joyeon Kang, Dong Keon Kim, Yoojeong Seo, Jongwook Yu, Hyeon Hee Lee, Jihye Park, Jae Jun Park, Jae Hee Cheon, Soo Jung Park, Tae Il Kim. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250294
- Open Access
- 6 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer
Small cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. Capping protein inhibiting regulator of actin dynamics ( CRACD ) that promotes actin polymerization, is frequently inactivated in SCLC. However, the role of CRACD loss in SCLC is unknown. Here we show that CRACD depletion drives neuroendocrine (NE) cell plasticity and immune evasion in SCLC. Mechanistically, CRACD inactivation disrupts actin organization, leading to suppression of Yap1-NOTCH signaling and subsequent NE gene upregulation. Simultaneously, CRACD loss drives EZH2-mediated histone methylation via nuclear actin disruption, leading to repression of MHC-I genes and depletion of CD8⁺ T cells. Consequently, CRACD-downregulated tumors exhibit increased cellular heterogeneity and escape from immune surveillance. Conversely, pharmacological inhibition of EZH2 restores MHC-I expression, reactivates antitumor immunity, and suppresses tumor growth. These findings identify CRACD as a tumor suppressor that constrains cell plasticity and immune evasion, highlighting the CRACD–EZH2–MHC-I axis as a potential therapeutic vulnerability in SCLC.
- 6 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessActin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer
Small cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. Capping protein inhibiting regulator of actin dynamics ( CRACD ) that promotes actin polymerization, is frequently inactivated in SCLC. However, the role of CRACD loss in SCLC is unknown. Here we show that CRACD depletion drives neuroendocrine (NE) cell plasticity and immune evasion in SCLC. Mechanistically, CRACD inactivation disrupts actin organization, leading to suppression of Yap1-NOTCH signaling and subsequent NE gene upregulation. Simultaneously, CRACD loss drives EZH2-mediated histone methylation via nuclear actin disruption, leading to repression of MHC-I genes and depletion of CD8⁺ T cells. Consequently, CRACD-downregulated tumors exhibit increased cellular heterogeneity and escape from immune surveillance. Conversely, pharmacological inhibition of EZH2 restores MHC-I expression, reactivates antitumor immunity, and suppresses tumor growth. These findings identify CRACD as a tumor suppressor that constrains cell plasticity and immune evasion, highlighting the CRACD–EZH2–MHC-I axis as a potential therapeutic vulnerability in SCLC.
- Open Access
Comparative single-cell transcriptomics of orthotopic and subcutaneous gastric tumors reveal immune and stromal heterogeneity
Preclinical cancer models often use subcutaneous (SC) implantation, which fails to recapitulate the native tumor microenvironment (TME) of orthotopic (ORT) sites. To resolve these differences, we used single-cell RNA sequencing (scRNA-seq) on paired SC and ORT implants of the CKP syngeneic gastric cancer model. Histopathological differences were minimal, but scRNA-seq revealed profound TME divergence. ORT tumors displayed robust stromal activation, coordinated fibroblast and endothelial signaling, and an immune compartment marked by higher T/NK cell activation and IgA-biased B cell plasma programs, reflecting a physiological mucosal environment. In contrast, SC tumors had higher overall T cell infiltration but showed markedly increased CD8+ T cell exhaustion and an enriched oxidative tumor program. Our findings provide critical guidance: SC models are optimal for high-throughput and exhaustion-focused assays, whereas ORT models are indispensable for studying organ-specific immune and stromal biology with translational fidelity.
Open AccessComparative single-cell transcriptomics of orthotopic and subcutaneous gastric tumors reveal immune and stromal heterogeneity
Preclinical cancer models often use subcutaneous (SC) implantation, which fails to recapitulate the native tumor microenvironment (TME) of orthotopic (ORT) sites. To resolve these differences, we used single-cell RNA sequencing (scRNA-seq) on paired SC and ORT implants of the CKP syngeneic gastric cancer model. Histopathological differences were minimal, but scRNA-seq revealed profound TME divergence. ORT tumors displayed robust stromal activation, coordinated fibroblast and endothelial signaling, and an immune compartment marked by higher T/NK cell activation and IgA-biased B cell plasma programs, reflecting a physiological mucosal environment. In contrast, SC tumors had higher overall T cell infiltration but showed markedly increased CD8+ T cell exhaustion and an enriched oxidative tumor program. Our findings provide critical guidance: SC models are optimal for high-throughput and exhaustion-focused assays, whereas ORT models are indispensable for studying organ-specific immune and stromal biology with translational fidelity.